Valganciclovir prophylaxis in patients at high risk for the development of cytomegalovirus disease
| Autor: | Jeffrey Rogers, Fuad Afzal, Kenneth D. Chavin, P.K. Baliga, S. Berkman, P. R. Rajagopalan, David J. Taber, G.M. Baillie, Angello Lin, Osemwegie E. Emovon, Elizabeth E. Ashcraft |
|---|---|
| Rok vydání: | 2004 |
| Předmět: |
Ganciclovir
Adult Male medicine.medical_specialty Opportunistic infection medicine.medical_treatment Population Pancreas transplantation Opportunistic Infections Antibodies Viral Gastroenterology Antiviral Agents Risk Factors Internal medicine medicine Humans Valganciclovir Drug Interactions education Kidney transplantation Antilymphocyte Serum Retrospective Studies Transplantation education.field_of_study Leukopenia business.industry Incidence (epidemiology) Middle Aged medicine.disease Kidney Transplantation Thrombocytopenia Infectious Diseases Immunology Cytomegalovirus Infections Female Pancreas Transplantation medicine.symptom business medicine.drug |
| Zdroj: | Transplant infectious disease : an official journal of the Transplantation Society. 6(3) |
| ISSN: | 1398-2273 |
| Popis: | Background. Despite advances in antiviral therapies, cytomegalovirus (CMV) remains the leading opportunistic infection in the transplant population. Valganciclovir (VGC), the l-valyl ester prodrug of ganciclovir (GCV), provides an excellent oral alternative to GCV for the prevention of CMV in transplant recipients. We investigated the use of VGC for CMV prevention in high-risk renal and pancreas transplant recipients. Methods. Patients at high risk for development of CMV disease were defined as either those who had donor positive, recipient-negative serostatus (D+/R−), or those who received antilymphocyte antibody (ALA) therapy for either rejection treatment or induction. A retrospective review was conducted of all kidney and pancreas transplants performed between August 2001 and December 2003. A total of 341 transplants were performed, of which 109 received VGC, and 88 were included in this analysis. Results. The overall incidence of CMV disease was 5.7% (5/88). All of the CMV episodes were in patients who were D+/R− (17.2% [5/29] versus 0% [0/59], P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|